138 related articles for article (PubMed ID: 28633892)
1. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis.
Bissett SL; Godi A; Jit M; Beddows S
Vaccine; 2017 Jul; 35(32):3922-3929. PubMed ID: 28633892
[TBL] [Abstract][Full Text] [Related]
2. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
[TBL] [Abstract][Full Text] [Related]
3. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
7. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
[TBL] [Abstract][Full Text] [Related]
8. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
9. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.
Stanley M; Joura E; Yen GP; Kothari S; Luxembourg A; Saah A; Walia A; Perez G; Khoury H; Badgley D; Brown DR
Vaccine; 2021 Apr; 39(16):2214-2223. PubMed ID: 33658126
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
Godi A; Kemp TJ; Pinto LA; Beddows S
J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
[TBL] [Abstract][Full Text] [Related]
11. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
Bissett SL; Draper E; Myers RE; Godi A; Beddows S
Vaccine; 2014 Feb; 32(10):1139-46. PubMed ID: 24440205
[TBL] [Abstract][Full Text] [Related]
12. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.
Draper E; Bissett SL; Howell-Jones R; Edwards D; Munslow G; Soldan K; Beddows S
Vaccine; 2011 Nov; 29(47):8585-90. PubMed ID: 21939712
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of high-risk HPV and its genotypes-Implications in the choice of prophylactic HPV vaccine.
Suresh A; Suresh P; Biswas R; Rajanbabu A; Sreedhar S; Biswas L
J Med Virol; 2021 Aug; 93(8):5188-5192. PubMed ID: 33851736
[TBL] [Abstract][Full Text] [Related]
15. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
Kemp TJ; Hildesheim A; Safaeian M; Dauner JG; Pan Y; Porras C; Schiller JT; Lowy DR; Herrero R; Pinto LA
Vaccine; 2011 Mar; 29(11):2011-4. PubMed ID: 21241731
[TBL] [Abstract][Full Text] [Related]
16. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.
Kann H; Lehtinen M; Eriksson T; Surcel HM; Dillner J; Faust H
J Infect Dis; 2021 Jun; 223(11):1992-2000. PubMed ID: 33009576
[TBL] [Abstract][Full Text] [Related]
17. Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine.
Kukimoto I; Matsumoto K; Takahashi F; Iwata T; Tanaka K; Yamaguchi-Naka M; Yamamoto K; Yahata H; Nakabayashi M; Kato H; Tsuda N; Onuki M; Yaegashi N;
Tohoku J Exp Med; 2020 Aug; 251(4):287-294. PubMed ID: 32759554
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.
Handisurya A; Schellenbacher C; Haitel A; Senger T; Kirnbauer R
Br J Cancer; 2016 Feb; 114(4):409-16. PubMed ID: 26867163
[TBL] [Abstract][Full Text] [Related]
19. High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus.
Konopnicki D; Manigart Y; Gilles C; Barlow P; De Marchin J; Feoli F; Delforge M; Clumeck N; De Wit S
AIDS; 2016 Jan; 30(3):425-33. PubMed ID: 26765936
[TBL] [Abstract][Full Text] [Related]
20. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
